British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.

Autor:	Suddle A; King's College Hospital NHS Foundation Trust, London, UK abid.suddle@nhs.net., Reeves H; Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK., Hubner R; Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK., Marshall A; Royal Free London NHS Foundation Trust, London, UK., Rowe I; University of Leeds, Leeds, UK.; St James's University Hospital, Leeds, UK., Tiniakos D; Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK., Hubscher S; Department of Pathology, University of Birmingham, Birmingham, UK., Callaway M; Division of Diagnostics and Therapies, University Hospitals Bristol NHS Trust, Bristol, UK., Sharma D; Royal Free Hospital, London, UK., See TC; Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hawkins M; Department of Medical Physics and Biomedical Engineering, University College London, London, UK., Ford-Dunn S; Western Sussex Hospitals NHS Foundation Trust, Worthing, UK., Selemani S; King's College Hospital NHS Foundation Trust, London, UK., Meyer T; Department of Oncology, University College, London, UK.
Jazyk:	angličtina
Zdroj:	Gut [Gut] 2024 Jul 11; Vol. 73 (8), pp. 1235-1268. Date of Electronic Publication: 2024 Jul 11.
DOI:	10.1136/gutjnl-2023-331695
Abstrakt:	Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu